A Phase 3 interventional study of Orforglipron and Placebo in Obesity, Overweight and Type 2 Diabetes, sponsored by Eli Lilly and Company. Completed at 136 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-04.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing orforglipron in Obesity — 4 open to participants now, 10 under way, 9 of them phase 3. orforglipron · Obesity.
Among the 22 studies testing orforglipron in Obesity, this one is the 3rd largest by enrollment, is one of 6 that started in 2023, is one of 14 in phase 3, and was the 6th registered.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →4 of the 22 studies testing orforglipron in Obesity are open now, in 12 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Belgium, Brazil and 10 more countries
Ages 6–17
Eli Lilly and Company · Sites in United States, Israel, Italy and 3 more countries
Ages 12–17
Eli Lilly and Company · Sites in China
Ages 18+
Massachusetts General Hospital · Sites in United States
Ages 18–80
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, orforglipron is the treatment under test here. Read study by study →
22 studies; the count open now beside each. This study's row is marked.
First in 2021; this study’s year is marked. 6 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,613 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 324 across the 22 interventional studies. Of the 12 that completed or were terminated, 8 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 22 have an industry lead sponsor. The 2 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
118 studies in Obesity by Eli Lilly and Company: 31 open now, 55 under way, 30 of them phase 3. Of 61 finished, 29 (48%) have results posted.
Among the 118 studies in Obesity by Eli Lilly and Company, this one is the 11th largest by enrollment of the 117 interventional ones that give a count, is one of 21 that started in 2023, is one of 51 in phase 3, and was the 30th registered.
Eli Lilly and Company’s Obesity studies by the year they started, since 2009.
5 of the studies testing orforglipron in Obesity that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06672549Phase 3Eli Lilly and CompanyA Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) | 2027-02 |
| NCT06993792Phase 3Eli Lilly and CompanyA Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes | 2027-08 |
| NCT06972459Phase 3Eli Lilly and CompanyA Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity | 2027-08 |
| NCT06972472Phase 3Eli Lilly and CompanyA Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes | 2027-08 |
| NCT06948435Phase 3Eli Lilly and CompanyA Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1 | 2027-09 |
Add all 5 to your calendar (.ics) → With an account.
Among the 22 studies testing orforglipron in Obesity, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 118 in Obesity:
This tab as a report to print or save as PDF → With an account.
This study will investigate the safety and efficacy of once daily oral treatment with orforglipron compared with placebo on body weight in adult participants with obesity or overweight and type 2 diabetes. The study will last about 77 weeks and may include up to 22 visits.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Have a diagnosis of Type 2 Diabetes (T2D), with ≥7% (≥53 mmol/mol) to ≤10% (86 mmol/mol) and are on stable treatment for T2D for at least 90 days prior to screening, consisting of:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received matching placebo capsule orally once daily (QD). Treatment was initiated with placebo corresponding to 1 milligram (mg) equivalent to Orforglipron, with dose escalation every 4 weeks to maintain blinding, and was continued through Week 72, unless dose modification was required.
Drug: Placebo
Participants received oral orforglipron capsule once daily. Treatment was initiated at 1 mg once daily, with dose escalation every 4 weeks to a target dose of 6 mg, which was maintained through Week 72, unless dose modification was required.
Drug: Orforglipron
Participants received oral orforglipron capsule once daily. Treatment was initiated at 1 mg once daily, with dose escalation every 4 weeks to a target dose of 12 mg, which was maintained through Week 72, unless dose modification was required.
Drug: Orforglipron
Participants received oral orforglipron capsule once daily. Treatment was initiated at 1 mg once daily, with dose escalation every 4 weeks to a target dose of 36 mg, which was maintained through Week 72, unless dose modification was required.
Drug: Orforglipron
Administered orally
Also known as: LY3502970
Administered orally
Percent Change From Baseline in Body Weight
Values represented under Least Squares (LS) Mean are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures with region + Baseline\*Time\*Treatment + Strata\*Time\*Treatment in the model. Strata were defined by joint levels of sex (female, male) and background oral antihyperglycemic medications (AHMs) classified according to their potential effect on body weight (promoting weight gain, weight reduction, or weight neutrality). Variance-covariance structure for change from baseline was unstructured.
Time frame: Baseline, Week 72
Percentage of Participants Who Achieved With Greater Than or Equal to (≥) 5% Body Weight Reduction From Baseline
Percentage of participants with ≥5% body weight reduction was analysed by Logistic regression with the following variables: region + Baseline\*Time\*Treatment + Strata\*Time\*Treatment in the model. Strata were defined by joint levels of sex (female, male) and background oral AHMs classified according to their potential effect on body weight (promoting weight gain, weight reduction, or weight neutrality).
Time frame: Baseline to Week 72
Percentage of Participants Who Achieved ≥10% Body Weight Reduction From Baseline
Percentage of participants with ≥10% body weight reduction was analysed by Logistic regression with the following variables: region + Baseline\*Time\*Treatment + Strata\*Time\*Treatment in the model. Strata were defined by joint levels of sex (female, male) and background oral AHMs classified according to their potential effect on body weight (promoting weight gain, weight reduction, or weight neutrality).
Time frame: Baseline to Week 72
Percentage of Participants Who Achieved ≥15% Body Weight Reduction From Baseline
Percentage of participants with ≥15% body weight reduction was analysed by Logistic regression with the following variables: region + Baseline\*Time\*Treatment + Strata\*Time\*Treatment in the model. Strata were defined by joint levels of sex (female, male) and background oral AHMs classified according to their potential effect on body weight (promoting weight gain, weight reduction, or weight neutrality).
Time frame: Baseline to Week 72
Change From Baseline in Waist Circumference
Values represented under Least Squares (LS) Mean are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures with region + Baseline\*Time\*Treatment + Strata\*Time\*Treatment in the model. Strata were defined by joint levels of sex (female, male) and background oral AHMs classified according to their potential effect on body weight (promoting weight gain, weight reduction, or weight neutrality). Variance-covariance structure for change from baseline was unstructured.
Time frame: Baseline, Week 72
Change From Baseline in Hemoglobin A1c (HbA1c) %
* Hemoglobin A1c (HbA1c) is the glycosylated fraction of hemoglobin A, measured to reflect average plasma glucose concentration over prolonged periods of time. * Values represented under Least Squares (LS) Mean are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures with region + Baseline\*Time\*Treatment + Strata\*Time\*Treatment in the model. Strata were defined by joint levels of sex (female, male) and background oral AHMs classified according to their potential effect on body weight (promoting weight gain, weight reduction, or weight neutrality). Variance-covariance structure for change from baseline was unstructured.
Time frame: Baseline, Week 72
Change From Baseline in Fasting Serum Glucose (FSG)
Values represented under Least Squares (LS) Mean are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures with region + Baseline\*Time\*Treatment + Strata\*Time\*Treatment in the model. Strata were defined by joint levels of sex (female, male) and background oral AHMs classified according to their potential effect on body weight (promoting weight gain, weight reduction, or weight neutrality). Variance-covariance structure for change from baseline was unstructured.
Time frame: Baseline, Week 72
Percentage of Participants Who Achieved Hemoglobin A1c (HbA1c) Target Value (<6.5%)
Percentage of participants who achieved hemoglobin A1c (HbA1c\<6.5%) was analysed by Logistic regression with the following variables: region + Baseline\*Time\*Treatment + Strata\*Time\*Treatment in the model. Strata were defined by joint levels of sex (female, male) and background oral AHMs classified according to their potential effect on body weight (promoting weight gain, weight reduction, or weight neutrality).
Time frame: Baseline to Week 72
Percentage of Participants Who Achieved Hemoglobin A1c (HbA1c) Target Value (<7.0%)
Percentage of participants who achieved hemoglobin A1c (HbA1c\<7%) was analysed by Logistic regression with the following variables: region + Baseline\*Time\*Treatment + Strata\*Time\*Treatment in the model. Strata were defined by joint levels of sex (female, male) and background oral AHMs classified according to their potential effect on body weight (promoting weight gain, weight reduction, or weight neutrality).
Time frame: Baseline to Week 72
Change From Baseline in Systolic Blood Pressure (SBP) (Pooled Doses of Orforglipron 6 mg, 12 mg and 36 mg)
Values represented under Least Squares (LS) Mean are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures with region + Baseline\*Time\*Treatment + Strata\*Time\*Treatment in the model. Strata were defined by joint levels of sex (female, male) and background oral AHMs classified according to their potential effect on body weight (promoting weight gain, weight reduction, or weight neutrality). Variance-covariance structure for change from baseline was unstructured.
Time frame: Baseline, Week 72
Change From Baseline in Diastolic Blood Pressure (DBP) (Pooled Doses of Orforglipron 6 mg, 12 mg and 36 mg)
Values represented under Least Squares (LS) Mean are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures with region + Baseline\*Time\*Treatment + Strata\*Time\*Treatment in the model. Strata were defined by joint levels of sex (female, male) and background oral AHMs classified according to their potential effect on body weight (promoting weight gain, weight reduction, or weight neutrality). Variance-covariance structure for change from baseline was unstructured.
Time frame: Baseline, Week 72
Percent Change From Baseline in Fasting Insulin
* Fasting Insulin is a test used to measure the amount of insulin in the body. * Values represented under "Geometric Least Squares Mean" are model-based estimates (MBE) of the unconditional average treatment effect. For post-baseline measures, MBE was calculated using a mixed-model repeated measures (MMRM) on log-transformed values, defined as log (Actual Measurement/Baseline) + Region + log (Baseline)\*Time\*Treatment + Strata\*Time\*Treatment in the model. Strata were defined by joint levels of sex (female, male) and background oral AHMs classified according to their potential effect on body weight (promoting weight gain, weight reduction, or weight neutrality). The variance-covariance structure was unstructured.
Time frame: Baseline, Week 72
Percent Change From Baseline in Non-High-Density Lipoprotein (Non-HDL) Cholesterol (Pooled Doses of Orforglipron 6 mg, 12 mg and 36 mg)
Values represented under "Geometric Least Squares Mean" are model-based estimates (MBE) of the unconditional average treatment effect. For post-baseline measures, MBE was calculated using a mixed-model repeated measures (MMRM) on log-transformed values, defined as log (Actual Measurement/Baseline) + Region + log (Baseline)\*Time\*Treatment + Strata\*Time\*Treatment in the model. Strata were defined by joint levels of sex (female, male) and background oral AHMs classified according to their potential effect on body weight (promoting weight gain, weight reduction, or weight neutrality). The variance-covariance structure was unstructured.
Time frame: Baseline, Week 72
Percent Change From Baseline in Triglycerides (Pooled Doses of Orforglipron 6 mg, 12 mg and 36 mg)
Values represented under "Geometric Least Square Mean" are model-based estimates (MBE) of the unconditional average treatment effect. For post-baseline measures, MBE was calculated using a mixed-model repeated measures (MMRM) on log-transformed values, defined on log-transformed values, defined as log (Actual Measurement/Baseline) + Region + log (Baseline)\*Time\*Treatment + Strata\*Time\*Treatment in the model. Strata were defined by joint levels of sex (female, male) and background oral AHMs classified according to their potential effect on body weight (promoting weight gain, weight reduction, or weight neutrality). The variance-covariance structure was unstructured.
Time frame: Baseline, Week 72
Change From Baseline in Short Form-36 Health Survey Version 2 (SF-36v2) Acute Form (Physical-Component and Mental-Component) Scores (Pooled Doses of Orforglipron 6 mg, 12 mg and 36 mg)
The SF-36v2 acute form, (1-week recall version) assesses participants' health-related quality of life on 8 domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. The physical functioning domain assesses limitations due to health "now," whereas the remaining domains assess functioning "in the past week." Each domain is scored individually, and information from these 8 domains is aggregated into 2 health component summary scores, the Physical Component Summary and Mental Component Summary. Items are answered on Likert scales of varying lengths (3-point, 5-point, or 6-point scales). Scoring of each domain and both summary scores are norm based and presented in the form of T-scores, with a mean of 50 and a standard deviation of 10. Higher scores indicate better levels of function and/or better health. Range cannot be specified in norm-based scores.
Time frame: Baseline, Week 72
| Milestone | Placebo | 6 mg Orforglipron QD | 12 mg Orforglipron QD | 36 mg Orforglipron QD |
|---|---|---|---|---|
| Started | 630 | 329 | 332 | 322 |
| Received at least one dose of study drug | 628 | 328 | 331 | 321 |
| Completed | 552 | 287 | 303 | 302 |
| Not completed | 78 | 42 | 29 | 20 |
| Withdrew: Adverse event | 5 | 7 | 6 | 3 |
| Withdrew: Death | 4 | 0 | 4 | 2 |
| Withdrew: Pregnancy | 1 | 0 | 0 | 1 |
| Withdrew: Lack of efficacy | 4 | 0 | 0 | 0 |
| Withdrew: Protocol deviation | 8 | 10 | 3 | 2 |
| Withdrew: Withdrawal by subject | 38 | 20 | 10 | 10 |
| Withdrew: Physician decision | 1 | 1 | 1 | 0 |
| Withdrew: Lost to follow-up | 17 | 4 | 5 | 2 |
Values represented under Least Squares (LS) Mean are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures with region + Baseline\*Time\*Treatment + Strata\*Time\*Treatment in the model. Strata were defined by joint levels of sex (female, male) and background oral antihyperglycemic medications (AHMs) classified according to their potential effect on body weight (promoting weight gain, weight reduction, or weight neutrality). Variance-covariance structure for change from baseline was unstructured.
| percent change | Placebo | 6 mg Orforglipron QD | 12 mg Orforglipron QD | 36 mg Orforglipron QD |
|---|---|---|---|---|
| Percent Change From Baseline in Body Weight | -2.21 ± 0.215 | -5.50 ± 0.356 | -7.78 ± 0.411 | -10.54 ± 0.466 |
Percentage of participants with ≥5% body weight reduction was analysed by Logistic regression with the following variables: region + Baseline\*Time\*Treatment + Strata\*Time\*Treatment in the model. Strata were defined by joint levels of sex (female, male) and background oral AHMs classified according to their potential effect on body weight (promoting weight gain, weight reduction, or weight neutrality).
| Percentage of participants | Placebo | 6 mg Orforglipron QD | 12 mg Orforglipron QD | 36 mg Orforglipron QD |
|---|---|---|---|---|
| Percentage of Participants Who Achieved With Greater Than or Equal to (≥) 5% Body Weight Reduction From Baseline | 24.4 | 49.8 | 60.2 | 72.8 |
Percentage of participants with ≥10% body weight reduction was analysed by Logistic regression with the following variables: region + Baseline\*Time\*Treatment + Strata\*Time\*Treatment in the model. Strata were defined by joint levels of sex (female, male) and background oral AHMs classified according to their potential effect on body weight (promoting weight gain, weight reduction, or weight neutrality).
| Percentage of participants | Placebo | 6 mg Orforglipron QD | 12 mg Orforglipron QD | 36 mg Orforglipron QD |
|---|---|---|---|---|
| Percentage of Participants Who Achieved ≥10% Body Weight Reduction From Baseline | 7.0 | 23.9 | 35.5 | 50.1 |
Percentage of participants with ≥15% body weight reduction was analysed by Logistic regression with the following variables: region + Baseline\*Time\*Treatment + Strata\*Time\*Treatment in the model. Strata were defined by joint levels of sex (female, male) and background oral AHMs classified according to their potential effect on body weight (promoting weight gain, weight reduction, or weight neutrality).
| Percentage of participants | Placebo | 6 mg Orforglipron QD | 12 mg Orforglipron QD | 36 mg Orforglipron QD |
|---|---|---|---|---|
| Percentage of Participants Who Achieved ≥15% Body Weight Reduction From Baseline | 1.9 | 7.3 | 17.7 | 28.4 |
Values represented under Least Squares (LS) Mean are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures with region + Baseline\*Time\*Treatment + Strata\*Time\*Treatment in the model. Strata were defined by joint levels of sex (female, male) and background oral AHMs classified according to their potential effect on body weight (promoting weight gain, weight reduction, or weight neutrality). Variance-covariance structure for change from baseline was unstructured.
| centimeters | Placebo | 6 mg Orforglipron QD | 12 mg Orforglipron QD | 36 mg Orforglipron QD |
|---|---|---|---|---|
| Change From Baseline in Waist Circumference | -2.67 ± 0.233 | -5.64 ± 0.394 | -7.16 ± 0.422 | -9.16 ± 0.437 |
* Hemoglobin A1c (HbA1c) is the glycosylated fraction of hemoglobin A, measured to reflect average plasma glucose concentration over prolonged periods of time. * Values represented under Least Squares (LS) Mean are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures with region + Baseline\*Time\*Treatment + Strata\*Time\*Treatment in the model. Strata were defined by joint levels of sex (female, male) and background oral AHMs classified according to their potential effect on body weight (promoting weight gain, weight reduction, or weight neutrality). Variance-covariance structure for change from baseline was unstructured.
| percentage of HbA1c | Placebo | 6 mg Orforglipron QD | 12 mg Orforglipron QD | 36 mg Orforglipron QD |
|---|---|---|---|---|
| Change From Baseline in Hemoglobin A1c (HbA1c) % | -0.14 ± 0.060 | -1.29 ± 0.069 | -1.60 ± 0.058 | -1.79 ± 0.059 |
Values represented under Least Squares (LS) Mean are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures with region + Baseline\*Time\*Treatment + Strata\*Time\*Treatment in the model. Strata were defined by joint levels of sex (female, male) and background oral AHMs classified according to their potential effect on body weight (promoting weight gain, weight reduction, or weight neutrality). Variance-covariance structure for change from baseline was unstructured.
| milligram per deciliter (mg/dL) | Placebo | 6 mg Orforglipron QD | 12 mg Orforglipron QD | 36 mg Orforglipron QD |
|---|---|---|---|---|
| Change From Baseline in Fasting Serum Glucose (FSG) | 1.2 ± 1.90 | -33.0 ± 2.13 | -41.1 ± 1.69 | -45.8 ± 1.79 |
Percentage of participants who achieved hemoglobin A1c (HbA1c\<6.5%) was analysed by Logistic regression with the following variables: region + Baseline\*Time\*Treatment + Strata\*Time\*Treatment in the model. Strata were defined by joint levels of sex (female, male) and background oral AHMs classified according to their potential effect on body weight (promoting weight gain, weight reduction, or weight neutrality).
| Percentage of participants | Placebo | 6 mg Orforglipron QD | 12 mg Orforglipron QD | 36 mg Orforglipron QD |
|---|---|---|---|---|
| Percentage of Participants Who Achieved Hemoglobin A1c (HbA1c) Target Value (<6.5%) | 10.6 | 56.2 | 67.5 | 75.0 |
Percentage of participants who achieved hemoglobin A1c (HbA1c\<7%) was analysed by Logistic regression with the following variables: region + Baseline\*Time\*Treatment + Strata\*Time\*Treatment in the model. Strata were defined by joint levels of sex (female, male) and background oral AHMs classified according to their potential effect on body weight (promoting weight gain, weight reduction, or weight neutrality).
| Percentage of participants | Placebo | 6 mg Orforglipron QD | 12 mg Orforglipron QD | 36 mg Orforglipron QD |
|---|---|---|---|---|
| Percentage of Participants Who Achieved Hemoglobin A1c (HbA1c) Target Value (<7.0%) | 23.0 | 70.0 | 78.0 | 85.1 |
Values represented under Least Squares (LS) Mean are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures with region + Baseline\*Time\*Treatment + Strata\*Time\*Treatment in the model. Strata were defined by joint levels of sex (female, male) and background oral AHMs classified according to their potential effect on body weight (promoting weight gain, weight reduction, or weight neutrality). Variance-covariance structure for change from baseline was unstructured.
| millimeters of mercury (mmHg) | Placebo | Pooled 6 mg/12 mg/36 mg Orforglipron QD |
|---|---|---|
| Change From Baseline in Systolic Blood Pressure (SBP) (Pooled Doses of Orforglipron 6 mg, 12 mg and 36 mg) | -1.48 ± 0.534 | -4.90 ± 0.414 |
Values represented under Least Squares (LS) Mean are model-based estimates (MBE) of the unconditional average treatment effect. MBE was calculated using a mixed-model repeated measures (MMRM) for post-baseline measures with region + Baseline\*Time\*Treatment + Strata\*Time\*Treatment in the model. Strata were defined by joint levels of sex (female, male) and background oral AHMs classified according to their potential effect on body weight (promoting weight gain, weight reduction, or weight neutrality). Variance-covariance structure for change from baseline was unstructured.
| millimeters of mercury (mmHg) | Placebo | Pooled 6 mg/12 mg/36 mg Orforglipron QD |
|---|---|---|
| Change From Baseline in Diastolic Blood Pressure (DBP) (Pooled Doses of Orforglipron 6 mg, 12 mg and 36 mg) | -1.39 ± 0.323 | -1.32 ± 0.261 |
* Fasting Insulin is a test used to measure the amount of insulin in the body. * Values represented under "Geometric Least Squares Mean" are model-based estimates (MBE) of the unconditional average treatment effect. For post-baseline measures, MBE was calculated using a mixed-model repeated measures (MMRM) on log-transformed values, defined as log (Actual Measurement/Baseline) + Region + log (Baseline)\*Time\*Treatment + Strata\*Time\*Treatment in the model. Strata were defined by joint levels of sex (female, male) and background oral AHMs classified according to their potential effect on body weight (promoting weight gain, weight reduction, or weight neutrality). The variance-covariance structure was unstructured.
| percent change | Placebo | 6 mg Orforglipron QD | 12 mg Orforglipron QD | 36 mg Orforglipron QD |
|---|---|---|---|---|
| Percent Change From Baseline in Fasting Insulin | -8.8 ± 2.54 | -6.4 ± 2.89 | -8.3 ± 3.18 | -18.0 ± 2.91 |
Values represented under "Geometric Least Squares Mean" are model-based estimates (MBE) of the unconditional average treatment effect. For post-baseline measures, MBE was calculated using a mixed-model repeated measures (MMRM) on log-transformed values, defined as log (Actual Measurement/Baseline) + Region + log (Baseline)\*Time\*Treatment + Strata\*Time\*Treatment in the model. Strata were defined by joint levels of sex (female, male) and background oral AHMs classified according to their potential effect on body weight (promoting weight gain, weight reduction, or weight neutrality). The variance-covariance structure was unstructured.
| percent change | Placebo | Pooled 6 mg/12 mg/36 mg Orforglipron QD |
|---|---|---|
| Percent Change From Baseline in Non-High-Density Lipoprotein (Non-HDL) Cholesterol (Pooled Doses of Orforglipron 6 mg, 12 mg and 36 mg) | -2.95 ± 1.182 | -6.41 ± 0.880 |
Values represented under "Geometric Least Square Mean" are model-based estimates (MBE) of the unconditional average treatment effect. For post-baseline measures, MBE was calculated using a mixed-model repeated measures (MMRM) on log-transformed values, defined on log-transformed values, defined as log (Actual Measurement/Baseline) + Region + log (Baseline)\*Time\*Treatment + Strata\*Time\*Treatment in the model. Strata were defined by joint levels of sex (female, male) and background oral AHMs classified according to their potential effect on body weight (promoting weight gain, weight reduction, or weight neutrality). The variance-covariance structure was unstructured.
| percent change | Placebo | Pooled 6 mg/12 mg/36 mg Orforglipron QD |
|---|---|---|
| Percent Change From Baseline in Triglycerides (Pooled Doses of Orforglipron 6 mg, 12 mg and 36 mg) | -4.70 ± 1.688 | -17.59 ± 1.096 |
The SF-36v2 acute form, (1-week recall version) assesses participants' health-related quality of life on 8 domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. The physical functioning domain assesses limitations due to health "now," whereas the remaining domains assess functioning "in the past week." Each domain is scored individually, and information from these 8 domains is aggregated into 2 health component summary scores, the Physical Component Summary and Mental Component Summary. Items are answered on Likert scales of varying lengths (3-point, 5-point, or 6-point scales). Scoring of each domain and both summary scores are norm based and presented in the form of T-scores, with a mean of 50 and a standard deviation of 10. Higher scores indicate better levels of function and/or better health. Range cannot be specified in norm-based scores.
| T-score | Placebo | Pooled 6 mg/12 mg/36 mg Orforglipron QD |
|---|---|---|
| Physical Component Score | 0.42 ± 0.271 | 1.47 ± 0.219 |
| Mental Component Score | -0.50 ± 0.270 | -0.10 ± 0.215 |
Collected over Baseline Up to Week 74. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 4/628 (0.6%) | 55/628 (8.8%) | 452/628 (72%) |
| 6 mg Orforglipron QD | 0/328 (0%) | 24/328 (7.3%) | 231/328 (70.4%) |
| 12 mg Orforglipron QD | 4/331 (1.2%) | 34/331 (10.3%) | 262/331 (79.2%) |
| 36 mg Orforglipron QD | 2/321 (0.6%) | 35/321 (10.9%) | 255/321 (79.4%) |
| Event | Placebo | 6 mg Orforglipron QD | 12 mg Orforglipron QD | 36 mg Orforglipron QD |
|---|---|---|---|---|
| Atrial fibrillationCardiac disorders | 2/628 | 3/328 | 0/331 | 1/321 |
| Urinary tract infectionInfections and infestations | 2/628 | 1/328 | 3/331 | 1/321 |
| Coronary artery diseaseCardiac disorders | 3/628 | 0/328 | 0/331 | 2/321 |
| Myocardial infarctionCardiac disorders | 1/628 | 0/328 | 2/331 | 2/321 |
| NephrolithiasisRenal and urinary disorders | 1/628 | 0/328 | 1/331 | 2/321 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 1/628 | 2/328 | 0/331 | 0/321 |
| DeathGeneral disorders | 0/628 | 0/328 | 2/331 | 0/321 |
| CholelithiasisHepatobiliary disorders | 1/628 | 0/328 | 2/331 | 1/321 |
| DiverticulitisInfections and infestations | 1/628 | 0/328 | 2/331 | 0/321 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 0/628 | 0/328 | 2/331 | 0/321 |
| Event | Placebo | 6 mg Orforglipron QD | 12 mg Orforglipron QD | 36 mg Orforglipron QD |
|---|---|---|---|---|
| HyperglycaemiaMetabolism and nutrition disorders | 247/628 | 43/328 | 32/331 | 27/321 |
| NauseaGastrointestinal disorders | 53/628 | 66/328 | 103/331 | 117/321 |
| DiarrhoeaGastrointestinal disorders | 94/628 | 70/328 | 82/331 | 88/321 |
| VomitingGastrointestinal disorders | 24/628 | 42/328 | 67/331 | 74/321 |
| ConstipationGastrointestinal disorders | 49/628 | 58/328 | 70/331 | 72/321 |
| DyspepsiaGastrointestinal disorders | 22/628 | 30/328 | 51/331 | 35/321 |
| Decreased appetiteMetabolism and nutrition disorders | 18/628 | 27/328 | 30/331 | 49/321 |
| EructationGastrointestinal disorders | 4/628 | 21/328 | 38/331 | 28/321 |
| Upper respiratory tract infectionInfections and infestations | 55/628 | 25/328 | 32/331 | 33/321 |
| NasopharyngitisInfections and infestations | 59/628 | 30/328 | 22/331 | 23/321 |
All randomized participants.
| Age, Continuous(years) | Placebo | 6 mg Orforglipron QD | 12 mg Orforglipron QD | 36 mg Orforglipron QD | Total |
|---|---|---|---|---|---|
| Mean | 56.5 ± 10.9 | 56.8 ± 10.4 | 56.2 ± 10.5 | 58.1 ± 10.8 | 56.8 ± 10.7 |
| Sex: Female, Male(Participants) | Placebo | 6 mg Orforglipron QD | 12 mg Orforglipron QD | 36 mg Orforglipron QD | Total |
|---|---|---|---|---|---|
| Female | 298 | 150 | 155 | 154 | 757 |
| Male | 332 | 179 | 177 | 168 | 856 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | 6 mg Orforglipron QD | 12 mg Orforglipron QD | 36 mg Orforglipron QD | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 194 | 102 | 95 | 97 | 488 |
| Not Hispanic or Latino | 416 | 221 | 229 | 218 | 1084 |
| Unknown or Not Reported | 20 | 6 | 8 | 7 | 41 |
| Race (NIH/OMB)(Participants) | Placebo | 6 mg Orforglipron QD | 12 mg Orforglipron QD | 36 mg Orforglipron QD | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 2 | 0 | 2 | 1 | 5 |
| Asian | 112 | 58 | 55 | 54 | 279 |
| Native Hawaiian or Other Pacific Islander | 3 | 2 | 1 | 0 | 6 |
| Black or African American | 37 | 21 | 19 | 28 | 105 |
| White | 442 | 238 | 235 | 228 | 1143 |
| More than one race | 22 | 5 | 12 | 6 | 45 |
| Unknown or Not Reported | 12 | 5 | 8 | 5 | 30 |
| Region of Enrollment(Participants) | Placebo | 6 mg Orforglipron QD | 12 mg Orforglipron QD | 36 mg Orforglipron QD | Total |
|---|---|---|---|---|---|
| Argentina | 59 | 31 | 31 | 28 | 149 |
| Australia | 35 | 18 | 19 | 20 | 92 |
| Brazil | 91 | 46 | 49 | 48 | 234 |
| China | 47 | 22 | 21 | 23 | 113 |
| Czechia | 74 | 40 | 42 | 38 | 194 |
| Germany | 67 | 34 | 35 | 34 | 170 |
| Greece | 29 | 18 | 16 | 15 | 78 |
| India | 35 | 18 | 18 | 18 | 89 |
| South Korea | 20 | 12 | 11 | 9 | 52 |
| United States | 173 | 90 | 90 | 89 | 442 |
| Baseline Weight(kilogram (kg)) | Placebo | 6 mg Orforglipron QD | 12 mg Orforglipron QD | 36 mg Orforglipron QD | Total |
|---|---|---|---|---|---|
| Mean | 101.19 ± 22.62 | 102.29 ± 22.74 | 102.71 ± 21.32 | 99.78 ± 22.99 | 101.45 ± 22.46 |
Showing the first 100 of 136 sites across 11 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Time Frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Jun 2023 to primary completion in Aug 2025, 26 months.
Results were first posted in Sep 2026, 1 year after primary completion.
Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 26 months is above that.
Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Orforglipron